Suchergebnisse - (Subject:"*Disease Progression")

PubPharm (5)

1

Antiprogrammed death ligand 1 therapy failed to reduce the risk of developing brain metastases in patients with extensive-stage small cell lung cancer : A retrospective analysis

enthalten in: Cancer | 2024

von Lu, S. | Guo, X. | Li, Y. | +3

2

A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy

enthalten in: Cancer | 2020

von Solem, C. | Bell, T. | Kwon, Y. | +5

3

Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L) : An open-label, randomized, phase 2 trial

enthalten in: Cancer | 2016

von Takeda, M. | Yamanaka, T. | Seto, T. | +17

CommentIn: Cancer. 2016 Apr 1;122(7):1047-9. - PMID 26828851

4

Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer

enthalten in: Cancer | 2015

von Lo, P. | Dahlberg, S. | Nishino, M. | +5

5

The nature and management of metastatic melanoma after progression on BRAF inhibitors : effects of extended BRAF inhibition

enthalten in: Cancer | 2014

von Chan, M. | Haydu, L. | Menzies, A. | +7

1
[1]